Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | KMT5B | Q4FZB7 | 2/20 | 0.50 |
| ▸ | KMT5C | Q86Y97 | 2/20 | 0.50 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8884638 | 1.00 | MAPT (0.59) | MAPTKDM4EGAAKMT5BKMT5C | |
| SCHEMBL29525969 | 0.91 | KDM4E (0.46) | MAPTKDM4EGAAKMT5BKMT5C | |
| SCHEMBL7173363 | 0.91 | KDM4E (0.46) | MAPTKDM4EGAAKMT5BKMT5C | |
| SCHEMBL3792292 | 0.86 | KDM4E (0.59) | MAPTKDM4EGAAKMT5BKMT5C | |
| SCHEMBL1270527 | 0.85 | CYP2D6 (0.48) | MAPTKDM4EGAAKMT5BKMT5C | |
| SCHEMBL3786467 | 0.84 | KMT5B (0.54) | MAPTKDM4EGAAKMT5BKMT5C | |
| SCHEMBL20837294 | 0.82 | MAPT (0.62) | MAPTKDM4EGAASMN1; SMN2ALDH1A1 | |
| SCHEMBL14092690 | 0.81 | ALOX15 (0.48) | MAPTKDM4EGAANPC1CYP2C19 | |
| SCHEMBL2361893 | 0.79 | KDM4E (0.59) | MAPTKDM4EGAAMEN1KMT2A | |
| SCHEMBL11964465 | 0.79 | MAPT (0.59) | MAPTKDM4EGAANPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2010-04-08 | — | — | US | disclosed |
| EP-1914221-A1 | PROCESS FOR PRODUCING BIARYL COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2008-04-23 | — | — | EP | disclosed |
| US-5661169-A | HAVE AFFINITY FOR VASOPRESSIN AND/OR OXYTOCIN RECEPTORS | SANOFI (FR) | 1997-08-26 | — | — | US | disclosed |
| US-5585394-A | INHIBITOR, ANTAGONIST OF VASOPRESSIN OR OXYTOCIN | SANOFI (FR) | 1996-12-17 | — | — | US | disclosed |
| EP-0694536-A1 | 1-Benzyl-1,3-dihydro-2H-benzimidazol-2-one derivatives, their preparation and pharmaceutical compositions containing them | SANOFI (FR) | 1996-01-31 | — | — | EP | disclosed |
| EP-0636614-A1 | Derivatives of 1-benzenesulfonyl-1,3-dihydro-2H-benzimidazol-2-one, their preparation and pharmaceutical compositions containing them | SANOFI (FR) | 1995-02-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | NISCH, BLVRB, BBOX1 | MAPT 3312/4885KDM4E 2606/4885GAA 1755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.